Allergen immunotherapy in asthma: Current evidence and future requirements

European Annals of Allergy and Clinical Immunology

Volumn 43, Issue 4, 2011, Pages 103-110

  Madonini, E ^a   Musarra, A ^b  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

^b Antonino Musarra   (Italy)

Author keywords

Allergen specific immunotherapy; Asthma; Efficacy; Outcomes

Indexed keywords

ALLERGEN; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; HOUSE DUST ALLERGEN; STEROID;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC ASTHMA; ARTICLE; ASTHMA; BRONCHUS REACTIVITY; CORTICOSTEROID THERAPY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOTHERAPY; META ANALYSIS (TOPIC); PEAK EXPIRATORY FLOW; SKIN SENSITIVITY; SKIN TEST; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, SUBLINGUAL; ADULT; ASTHMA; BRONCHIAL HYPERREACTIVITY; CHILD; CLINICAL TRIALS AS TOPIC; DESENSITIZATION, IMMUNOLOGIC; EUROPE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; UNITED STATES;

EID: 80052700323     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Adkinson NF, Jr. Con: Immunotherapy is not clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001;164(12):2140-1.
2. Barnes PJ. Is immunotherapy for asthma worthwhile? N Engl J Med 1996;334(8):531-2.
3. Bousquet J. Pro: Immunotherapy is clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001;164(12):2139-40.
4. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitz- Gerald M, et al. Global strategy for asthma management and prevention: GINA executive summar y. Eur Respir J 2008;31(1):143-78.
5. Cox L. Allergen immunotherapy and asthma: efficacy, safety, and other considerations. Allergy Asthma Proc 2008;29(6):580-9.
6. Cruz AA, Popov T, Pawankar R, Annesi-Maesano I, Fokkens W, Kemp J, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007;62 Suppl 84:1-41.
7. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. Clin Exp Allergy 2011;DOI 10.1111/j.1365-2222.2010.03688.x
8. Bonifazi F, Bilo MB. Efficacy of specific immunotherapy in allergic asthma: myth or reality? Allergy 1997;52(7):698-710.
9. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. AWHO position paper. J Allergy Clin Immunol 1998;102(4 Pt 1):558-62.
10. Calderon MA, Boyle RJ, Penagos M, Sheikh A. Immunotherapy: The Meta-Analyses. What have we Learned? Immunol Allergy Clin North Am 2011;31(2):159-73.
11. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010(8):CD001186.
12. Calamita Z, Saconato H, Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized- clinical trials using the Cochrane Collaboration method. Allergy 2006;61(10):1162-72.
13. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008;133(3):599-609.
14. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol 2005;15(1):9-16.
15. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009;64(11):1570-9.
16. Abramson MJ, Puy RM,Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995;151(4):969-74.
17. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2000(2):CD001186.
18. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003(4):CD001186.
19. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther 2000;22(3):329-41.
20. Larenas-Linnemann DE, Cox LS. Sublingual immunotherapy for asthma: need for high quality meta-analyses to prove the concept. Allergy 2007;62(6):704-5; author reply 06-7.
21. Nieto A, Mazon A, Pamies R, Bruno L, Navarro M, Montanes A. Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses. J Allergy Clin Immunol 2009;124(1):157-61 e1-32.
22. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010;126(3):558-66.
23. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64 Suppl 91:1-59.
24. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011;127(1 Suppl):S1-55.
25. Rank MA, Oslie CL, Krogman JL, Park MA, Li JT. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 2008;29(4):400-5.
26. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen- specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010;126(5):942-9.
27. Adkinson NF, Jr., Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336(5):324-31.
28. Nagata M, Nakagome K. Allergen immunotherapy in asthma: current status and future perspectives. Allergol Int 2010;59(1):15-9.
29. Mohapatra SS, Qazi M, Hellermann G. Immunotherapy for allergies and asthma: present and future. Curr Opin Pharmacol 2010;10(3):276-88.
30. Incorvaia C, Riario-Sforza GG, Incorvaia S, Frati F. Sublingual immunotherapy in allergic asthma: Current evidence and needs to meet. Ann Thorac Med 2010;5(3):128-32.
31. Alzakar RH, Alsamarai AM. Efficacy of immunotherapy for treatment of allergic asthma in children. Allergy Asthma Proc 2010;31(4):324-30.
32. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102(1):22-8.
33. EMA/PDCO Standard Paediatric Investigation Plan for Allergen Products for Specific Immunotherapy. 3 March 2010. EMA/PDCO/737605/2009.
34. European Medicines Agency. Guideline On The Clinical Development Of Products For Specific Immunotherapy For The Treatment Of Allergic Diseases. London, 20 November 2008. Doc. Ref. CHMP/EWP/18504/2006.
35. Bousquet PJ, Calderon MA, Demoly P, Larenas D, Passalacqua G, Bachert C, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011;127(1):49-56, 56 e1-11.
36. Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62(3):317-24.
37. C. New regulatory documents and procedures. I: Guideline on clinical trials of SIT products, European Pharmacopoeia, and note for guidance on allergen products. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf AM2009;96:187-90; discussion 91-2.
38. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127(1):30-8.
39. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61(7):843-8.
40. Hedlin G, Wille S, Browaldh L, Hildebrand H, Holmgren D, Lindfors A, et al. Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999;103(4):609-14.
41. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006;117(2):263-8.
42. Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebocontrolled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002;109(5):777-83.
43. Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 2011;127(2):502-08 e1-6.
44. Marogna M, Spadolini I, Massolo A, Berra D, Zanon P, Chiodini E, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol 2009;102(1):69-75.
45. Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007;18(6):508-15.
46. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double- blind, placebo-controlled study. Allergy 1999;54(3):249-60.
47. Vourdas D, Syrigou E, Potamianou P, Carat F, Batard T, Andre C, et al. Double-blind, placebo-controlled evaluation ofgual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998;53(7):662-72.
48. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebocontrolled study. Allergy 2000;55(9):842-9.
49. Jacobsen L, Valovirta E. How strong is the evidence that immunotherapy in children prevents the progression of allergy and asthma? Curr Opin Allergy Clin Immunol 2007;7(6):556-60.
50. Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109(2):251-6.
51. Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114(4):851-7.
52. Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco AD, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008;101(2):206-11.
53. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-138.
54. Sykes A, Seemungal T. Recent advances in exacerbations of asthma. Thorax 2008;63(9):758-60.
55. Rodriguez Santos O. [Sublingual immunotherapy in allergic rhinitis and asthma in 2-5 year-old children sensitized to mites]. Rev Alerg Mex 2008;55(2):71-5.
56. Chen ZG, Li M, Chen YF, Ji JZ, Li YT, Chen W, et al. Effects of dermatophagoides pteronyssinus allergen-specific immunotherapy on the serum interleukin-13 and pulmonary functions in asthmatic children. Chin Med J (Engl) 2009;122(10):1157-61.
57. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol 2007;18(1):47-57.
58. Maestrelli P, Zanolla L, Pozzan M, Fabbri LM. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 2004;113(4):643-9.
59. Bousquet J, Michel FB, Malling HJ. Immunotherapy for asthma. N Engl J Med 1997; 336(26):1912; author reply 13.
60. Coifman RE. Immunotherapy for asthma. N Engl J Med 1997;336(26):1911-2; author reply 13.
61. Gordon BR. Immunotherapy for asthma. N Engl J Med 1997;336(26):1912; author reply 13.
62. JT. Immunotherapy for asthma. N Engl J Med 1997;336(26):1912; author reply 13.
63. Adkinson NF, Jr. Who (if anyone) actually gets steroid-sparing effects from aeroallergen immunotherapy? J Allergy Clin Immunol 2010;126(5):950-1.
64. Bieber T, Simon HU. Allergen-specific immunotherapy: current concepts and future directions. Allergy 2011;66(6):709-12.
65. Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol 2011;127(1):8-15.